<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21866" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Folinic Acid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gristan</surname>
            <given-names>Yana D.</given-names>
          </name>
          <aff>Ross University/Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moosavi</surname>
            <given-names>Leila</given-names>
          </name>
          <aff>Kern Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yana Gristan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leila Moosavi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21866.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Folinic acid, also known as 5-formyl tetrahydrofolic acid or leucovorin, treats various cancers when employed with 5-fluorouracil (5-FU). Additionally, leucovorin serves as an antidote to folic acid antagonists like methotrexate. Folinic acid's properties allow it to function as an antidote, chemotherapy-modulating agent, and rescue agent for the chemotherapy category of medications. This activity will discuss the approved indications, intricate mechanism of action, and contraindications for folinic acid while&#x000a0;addressing&#x000a0;its role in treating specific cancer types and megaloblastic anemia. The activity will also discuss the adverse event profile, off-label applications, and monitoring protocols associated with folinic acid, offering insights for the interprofessional team involved in the care of patients undergoing treatment with 5-FU, methotrexate, and other conditions where folinic acid proves indispensable.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate clinical indications for folinic acid supplementation, distinguishing between various conditions and patient populations where it may be beneficial.</p></list-item><list-item><p>Implement folinic acid therapy per evidence-based guidelines, considering proper dosing, route of administration, and monitoring requirements for specific clinical scenarios.</p></list-item><list-item><p>Apply knowledge of potential adverse effects, contraindications, and drug interactions associated with folinic acid to minimize risks and ensure patient safety.</p></list-item><list-item><p>Develop effective communication with patients and their caregivers regarding the benefits, risks, and expectations of folinic acid therapy, fostering informed decision-making and treatment adherence.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21866&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21866">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21866.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Folinic acid,&#x000a0;or 5-formyl tetrahydrofolic acid, is a naturally occurring, reduced form of folic acid commonly known in clinical practice as leucovorin. Often, clinicians use the terms folic acid and folinic acid interchangeably, but they are not the same. Folic acid is a synthetic, oxidized, and water-soluble form of folate (vitamin B9) used therapeutically and does not exist in nature, whereas folinic acid exists naturally and is biologically active.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref> Both compounds are&#x000a0;included in the &#x0201c;folate&#x0201d;&#x000a0;category and are dietary&#x000a0;forms of vitamin B9, found in foods such as leafy green vegetables.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref></p>
        <p>Indications for folate supplementation include preventing several diseases, such as ulcerative colitis, neural tube defects, and cognitive dysfunction in older patients.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref> Folinic acid represents over 90% of functional folate derivatives in plasma. Therapeutic uses of folinic acid have become essential in modern clinical practice, mainly because humans cannot synthesize folates de novo.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref> Clinicians consider folinic acid supplementation superior to folic acid supplementation because folinic acid can reach higher concentrations in plasma and function in the face of defective folate metabolism.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref>&#x000a0;The names folinic acid and leucovorin will be used interchangeably throughout this activity.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA-approved indications of folinic acid are listed below.<xref ref-type="bibr" rid="article-21866.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Increased levels of folinic acid potentiate the cytotoxic effects of 5-FU in the cell.<xref ref-type="bibr" rid="article-21866.r3">[3]</xref> This finding has revolutionized the treatment of several cancers, most notably colorectal cancer,&#x000a0;which, according to the American Cancer Society, represents the&#x000a0;third leading cause of cancer-related death in both sexes.<xref ref-type="bibr" rid="article-21866.r4">[4]</xref><xref ref-type="bibr" rid="article-21866.r1">[1]</xref> The combination of folinic acid with 5-FU is an FDA-approved indication for the palliative treatment of colorectal cancer. Specifically, patients with advanced, nonresectable adenocarcinoma of the colon who are receiving treatment with folinic acid and 5-FU display more prolonged progression-free survival and response rates.<xref ref-type="bibr" rid="article-21866.r3">[3]</xref> High-dose folinic acid/5-FU regimens can also be used as adjuvant therapy for resectable colorectal cancer. Folinic acid aids in producing a significant increase in disease-free survival compared to patients who receive treatment with surgical resection alone.<xref ref-type="bibr" rid="article-21866.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As a folic acid derivative, folinic acid is helpful as an antidote to folic acid antagonists (ie, methotrexate and pyrimethamine).<xref ref-type="bibr" rid="article-21866.r6">[6]</xref> Frequently referred to as &#x0201c;leucovorin rescue,&#x0201d; folinic acid is used to&#x000a0;manage the toxic effects of high-dose methotrexate therapy.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref> Methotrexate has a variety of indications in the treatment of various malignancies and immunologic disorders. Thus, all&#x000a0;conditions requiring methotrexate therapy, especially in high dosages, benefit from folinic acid as rescue therapy.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref> As an antidote, folinic acid limits myelosuppression, gastrointestinal toxicity, nephrotoxicity, and neurotoxicity that can result secondary to high dosages of methotrexate and other folic acid antagonists.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref> Study results show that administering folinic acid after weekly doses of methotrexate reduces the incidence of transaminitis (hepatic damage), gastrointestinal complications, and stomatitis (oral ulcers).<xref ref-type="bibr" rid="article-21866.r7">[7]</xref>&#x000a0;Supplementing&#x000a0;folinic acid&#x000a0;during methotrexate therapy is so essential that chemotherapy protocols using methotrexate also include detailed recommendations regarding folinic acid rescue administration.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref> For&#x000a0;reducing toxicity and counteracting the effects of high-dose methotrexate, folinic acid is FDA-approved in both adults and children.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The intravenous formulation of folinic acid (leucovorin calcium) is also FDA-approved for use in adults and children (recommendation IIa, strength of evidence category B) to treat megaloblastic anemia in patients who have normal vitamin B12 levels and in whom oral therapy is not possible.<xref ref-type="bibr" rid="article-21866.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Folinic acid is also approved to treat folate-deficiency-associated megaloblastic anemia.</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>Non-FDA-approved&#x000a0;uses for&#x000a0;folinic acid&#x000a0;include: &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Treating Breast Cancer: Similar to its use in colorectal cancer, folinic acid has also been shown to potentiate the effects of 5-FU. This regimen is currently non-FDA approved, partly because there is insufficient evidence that folinic acid can increase the therapeutic index of 5-FU in breast cancer and because many such clinical trials are ongoing.<xref ref-type="bibr" rid="article-21866.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Regimens including folinic acid and 5-FU also have non-FDA-approved indications for treating unresectable/advanced gallbladder and biliary tree carcinoma,&#x000a0;gastric cancer,&#x000a0;squamous cell carcinoma of the head and neck,&#x000a0;and resectable pancreatic cancer.<xref ref-type="bibr" rid="article-21866.r9">[9]</xref><xref ref-type="bibr" rid="article-21866.r10">[10]</xref><xref ref-type="bibr" rid="article-21866.r11">[11]</xref><xref ref-type="bibr" rid="article-21866.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Combination chemotherapy regimens that include folinic acid have been effective in various non-Hodgkin lymphomas. Methotrexate and rescue folinic acid, combined with other chemotherapy agents (ie, doxorubicin, cyclophosphamide), have shown a complete response rate of 84% in treating diffuse large cell lymphoma.<xref ref-type="bibr" rid="article-21866.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>For patients who require prophylactic therapy for toxoplasmosis and who are unable to tolerate sulfamethoxazole/trimethoprim, folinic acid is recommended in combination with clindamycin and pyrimethamine as an alternative. Folinic acid, in conjunction with pyrimethamine and sulfadoxine, is another option.<xref ref-type="bibr" rid="article-21866.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>For patients requiring prophylactic treatment for <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia and who cannot tolerate sulfamethoxazole/trimethoprim, an alternative therapy can be used that includes folinic acid in combination with pyrimethamine and dapsone, among other combinations.<xref ref-type="bibr" rid="article-21866.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Serum plasma levels of homocysteine and folate derivatives have an inverse relationship.&#x000a0;In particular, the methionine cycle, which uses homocysteine as a substrate, is sensitive to folate deficiency.&#x000a0;Thus, plasma homocysteine levels are markedly increased when cells have functional depletion of folinic acid.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref> In patients with hyperhomocysteinemia, folinic acid has been found to reduce the plasma level of homocysteine, particularly in patients on hemodialysis.<xref ref-type="bibr" rid="article-21866.r16">[16]</xref> This finding suggests that folinic acid intake may reduce the risk of cardiovascular disease. Furthermore, folinic acid levels can be an indirect indicator of homocysteine levels.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with repeated nitrous oxide exposure or requiring treatment with long-term nitrous oxide may benefit from folinic acid prophylaxis to prevent bone marrow suppression.<xref ref-type="bibr" rid="article-21866.r17">[17]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21866.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Folates and folic acid are not biologically active and must be converted into tetrahydrofolate through dihydrofolate reductase. Folinic acid does not require dihydrofolate reductase for conversion into tetrahydrofolate.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref> Tetrahydrofolate and its derivatives then participate in thymidylate and purine synthesis as they are essential in carrying out one-carbon transfer reactions in vivo.<xref ref-type="bibr" rid="article-21866.r18">[18]</xref> These reactions are essential in the generation of nucleic acids, the regulation of gene expression, and the overall stability of the genome.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref><xref ref-type="bibr" rid="article-21866.r18">[18]</xref> Serine, methionine, histidine, and glycine metabolism also depend on such substrates and reactions. Thus, folinic acid ultimately plays a crucial role in normal metabolism and gene regulation.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref> Furthermore, folinic acid is essential for synthesizing methionine from homocysteine, as this is a methylation reaction.<xref ref-type="bibr" rid="article-21866.r1">[1]</xref></p>
        <p>The&#x000a0;2 main roles of folinic acid in pharmacology are to counteract the effects of folic acid antagonists and enhance the impact of fluoropyrimidines.<xref ref-type="bibr" rid="article-21866.r19">[19]</xref> The former function is possible because folinic acid can enter cells through the reduced folate carrier and subsequently be converted to tetrahydrofolate despite the presence of methotrexate, thereby &#x0201c;rescuing&#x0201d; these cells from methotrexate toxicity.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref></p>
        <p>Most folic acid antagonists share a similar mechanism of action that includes the inhibition of dihydrofolate reductase, the enzyme responsible for generating the functional tetrahydrofolate molecule. Folinic acid does not require dihydrofolate reductase to convert into its active derivatives. In this setting, folinic acid is an antidote that rescues these cells from the chemotherapeutic toxicities of folate antagonists such as methotrexate.<xref ref-type="bibr" rid="article-21866.r18">[18]</xref></p>
        <p>While folinic acid counts the adverse effects of methotrexate,&#x000a0;the drug functions to enhance the effects of 5-FU. In the cell, 5-FU converts to fluoro-deoxy uridylic acid, a molecule that inhibits thymidylate synthase. Thymidylate synthase is an enzyme that is important in DNA repair and replication. The functional derivative of folinic acid, 5,10 methylenetetrahydrofolate, stabilizes the bound fluoro-deoxy uridylic acid to thymidylate synthase. This interaction yields a ternary complex known as the thymidylate synthase 5-fluorodeoxyuridine monophosphate-methylenetetrahydrofolate complex,&#x000a0;which inhibits thymidylate synthase. Increased cellular amounts of folinic acid derivatives lead to increased stability of the aforementioned inhibitory complex, which leads to a depletion of thymidylate synthesis and disrupts DNA synthesis and repair.<xref ref-type="bibr" rid="article-21866.r19">[19]</xref><xref ref-type="bibr" rid="article-21866.r2">[2]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Folinic acid is rapidly and almost completely absorbed following oral administration. Bioavailability is dose-dependent.<xref ref-type="bibr" rid="article-21866.r19">[19]</xref></p>
        <p><bold>Distribution:</bold>&#x000a0;IV administration results in a greater volume of distribution than oral, with oral dosing showing a lower&#x000a0;maximum blood concentration primarily due to first-pass metabolism.<xref ref-type="bibr" rid="article-21866.r19">[19]</xref></p>
        <p><bold>Metabolism:</bold> Folinic acid is metabolized in the liver and GI tract and has an active metabolite. The average half-life is approximately 6 hours.</p>
        <p><bold>Elimination:</bold> Excretion is 80% to 90% in urine and 5% to 8% in the feces.</p>
      </sec>
      <sec id="article-21866.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Folinic acid/leucovorin is available in 5, 10, 15, and 25 mg tablets. Injectable formulations are&#x000a0;10 and 20 mg/mL solutions.&#x000a0;Folinic acid is usually compounded with calcium, so it should not be administered intravenously at rates &#x0003e;160 mg/min. Folinic acid is also not to be administered intrathecally.<xref ref-type="bibr" rid="article-21866.r20">[20]</xref></p>
        <p>Due to the wide range of folinic acid indications and administration guidelines, specific protocols are available that clinicians should follow; the dosing regimens below are general and are not a replacement for checking the facility protocols. In general, folinic acid is compounded with leucovorin calcium (especially for FDA-approved indications) and can be administered intramuscularly, intravenously, or orally. The timing, dosage, and route of folinic acid administration depend on the desired outcome for the&#x000a0;particular indication.<xref ref-type="bibr" rid="article-21866.r19">[19]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>For high-dose methotrexate leucovorin rescue,&#x000a0;the dosage is typically 15 mg orally, IM, or IV every 6 hours for 10 doses, starting 24 hours after initiating methotrexate. The maximum oral dose is 25 mg; IM or IV doses may be higher.</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with&#x000a0;delayed methotrexate administration, the dosage is 15 mg orally, IM, or IV every 6 hours. Continue until the methotrexate level &#x0003c;0.05 micromolar.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>For leucovorin rescue for methotrexate overdose, the dosage is typically 10 mg/m<sup>2</sup>&#x000a0;orally, IM, or IV every 6 hours, starting ASAP after overdose or within 24 hours if delayed methotrexate elimination.</p>
        <p>For&#x000a0;folate antagonist overdose:</p>
        <list list-type="bullet">
          <list-item>
            <p>For pemetrexed:&#x000a0;50 mg/m<sup>2</sup>/dose IV every 6 hours for 8 days. Start with 100 mg/m<sup>2</sup>/dose IV for the first dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For trimethoprim or pyrimethamine: Give 5 to 15&#x000a0;mg orally, IM, or IV daily until the restoration of hematopoiesis.</p>
          </list-item>
        </list>
        <p>For colorectal cancer combination therapy with 5-FU, clinicians should follow specific administration schedules as individual protocols vary. In general, when used for combination therapy, folinic acid is administered as an IV bolus or short IV infusions (minutes to hours).<xref ref-type="bibr" rid="article-21866.r2">[2]</xref>&#x000a0;Dosing may require adjustments based on toxicity.</p>
        <list list-type="bullet">
          <list-item>
            <p>With 5-FU 370 mg/m<sup>2</sup>/d: Leucovorin 200 mg/m<sup>2</sup>/d administered IV on days 1 to 5 of a 28-day cycle. Give 2 cycles, then continue 28-day cycles or extend to 35-day cycles.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>With&#x000a0;5-FU&#x000a0;425 mg/m<sup>2</sup>/d: Leucovorin 20 mg/m<sup>2</sup>/d administered IV on days 1 to 5 of a 28-day cycle. Give 2 cycles, then continue 28-day cycles or extend to 35-day cycles.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Folate-deficiency&#x000a0; associated megaloblastic anemia:
<list list-type="bullet"><list-item><p>Dosing is &#x0003c;1 mg IV daily; maximum dose 1 mg daily.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>As with adult dosing recommendations, individual protocols require close adherence, as guidelines differ depending on the desired outcome and particular indication. However, there are similar generalities in both patient populations. For both methotrexate toxicity and combination therapy with 5-FU, the&#x000a0;previously mentioned adult administration recommendations&#x000a0;are similar for the pediatric patient population.<xref ref-type="bibr" rid="article-21866.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>For high-dose methotrexate leucovorin rescue:
<list list-type="bullet"><list-item><p>In patients with standard methotrexate administration, the dosage is 10 mg/m<sup>2</sup>/dose, orally, IM, or IV every 6 hours for 10 doses, starting 24 hours after initiating methotrexate. The maximum oral dose is 25 mg; IM or IV doses may be higher.</p></list-item><list-item><p>In patients with&#x000a0;delayed methotrexate administration, the dosage is mg/m<sup>2</sup>/dose orally, IM, or IV every 6 hours. Continue until the methotrexate level &#x0003c;0.05 &#x003bc;M.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Leucovorin rescue for methotrexate overdose: Dosage is&#x000a0;10 mg/m<sup>2</sup>/dose orally, IM, or IV every 6 hours, starting ASAP after overdose or within 24 hours if delayed methotrexate elimination.</p>
          </list-item>
          <list-item>
            <p>For folate antagonist overdose:</p>
            <list list-type="bullet">
              <list-item>
                <p>For trimethoprim or pyrimethamine: Give 5 to 15&#x000a0;mg orally, IM, or IV daily until the restoration of hematopoiesis.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Folate-deficiency-associated megaloblastic anemia:</p>
            <list list-type="bullet">
              <list-item>
                <p>Dosing is &#x0003c;1 mg IV daily; maximum dose 1 mg daily.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> Dosing in hepatic impairment is undefined.</p>
        <p><bold>Renal impairment:</bold> Dosing for patients with renal impairment, including those on dialysis, is undefined.</p>
        <p><bold>Pregnant women:</bold> Folinic acid/leucovorin may be used during pregnancy; human data&#x000a0;shows&#x000a0;no known risk of fetal harm.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Folinic acid can be used by breastfeeding women. No human data is available, but based on the drug's properties, infant harm is not expected.</p>
        <p><bold>Older patients:</bold> No data specific to leucovorin prohibits or limits its use in older&#x000a0;patients.</p>
      </sec>
      <sec id="article-21866.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Because folinic acid administration is usually combined with chemotherapy agents, it is challenging to discern causative relationships between folinic acid and adverse effects compared to the chemotherapeutic agents with which they are coadministered. The most commonly reported adverse reactions to folinic acid include GI upset (nausea, vomiting, diarrhea), leukopenia, alopecia, and stomatitis. Other adverse outcomes include erythema, pruritus, skin rash, and urticaria.<xref ref-type="bibr" rid="article-21866.r21">[21]</xref>&#x000a0;Although rare, anaphylactic reactions are possible following the administration of folinic acid.<xref ref-type="bibr" rid="article-21866.r22">[22]</xref></p>
        <p>Hypocalcemia can result in patients being treated with folinic acid. Studies suggest that there is evidence of decreased vitamin D levels in such patients, which may contribute to hypocalcemia. Thus, there is a recommendation for calcium monitoring and appropriate supplementation as needed.<xref ref-type="bibr" rid="article-21866.r23">[23]</xref>&#x000a0;</p>
        <p>Gastrointestinal complications are found to be more frequent and severe when adding folinic acid to 5-FU therapy, particularly in treating colorectal cancer. Patients treated with folinic acid in conjunction with 5-FU were found to have a higher incidence of stomatitis and diarrhea than patients treated with 5-FU alone. Patients who experience gastrointestinal adverse effects should not receive further combination treatment until GI toxicity resolves, regardless of severity. Patients with GI toxicity, particularly those with diarrhea,&#x000a0;can deteriorate&#x000a0;rapidly. These patients&#x000a0;require close monitoring, especially older or patients with disabilities.<xref ref-type="bibr" rid="article-21866.r24">[24]</xref>&#x000a0;Older patients can potentially develop severe enterocolitis, diarrhea, and dehydration that may result in death.<xref ref-type="bibr" rid="article-21866.r25">[25]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Leucovorin should not be used with the following agents:</p>
        <list list-type="bullet">
          <list-item>
            <p>Capecitabine: potential risk of 5-FU toxicity from synergistic effects.</p>
          </list-item>
          <list-item>
            <p>Pafolacianine: this combination may decrease pafolacianine binding to ovarian cancer cells.</p>
          </list-item>
          <list-item>
            <p>Sulfamethoxazole: this combination may reduce the therapeutic effects of sulfamethoxazole.</p>
          </list-item>
          <list-item>
            <p>Trimethoprim: this combination may decrease the&#x000a0;effectiveness of trimethoprim against pneumocystis pneumonia.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21866.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As mentioned earlier, patients who develop GI toxicity with a combination of 5-FU and folinic acid therapy should no longer receive such treatment until symptoms have resolved.<xref ref-type="bibr" rid="article-21866.r24">[24]</xref>&#x000a0;Intrathecal administration is also contraindicated. Hypersensitivity to folinic acid or its components are contraindications to its administration.<xref ref-type="bibr" rid="article-21866.r20">[20]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Caution is necessary for patients receiving folinic acid therapy to treat megaloblastic anemia, particularly with concurrent vitamin B12 deficiency or pernicious anemia. In such cases, neurologic manifestations may progress and get masked by hematologic remission.<xref ref-type="bibr" rid="article-21866.r8">[8]</xref></p>
      </sec>
      <sec id="article-21866.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In patients treated for megaloblastic anemia, hematologic monitoring (ie, complete blood counts) showing improvement generally indicates efficacy.<xref ref-type="bibr" rid="article-21866.r8">[8]</xref></p>
        <p>In patients treated with folinic acid for methotrexate toxicity,&#x000a0;the recommendation is to monitor serum creatinine and methotrexate levels at 24-hour intervals.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref> A significant decrease in urine output or increased serum creatinine is a sign of a medical emergency in high-dose methotrexate therapy. Aggressive monitoring of methotrexate levels, early recognition of delayed methotrexate excretion, and prompt administration of&#x000a0;leucovorin rescue therapy are imperative in reducing morbidity and mortality in such patients.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref></p>
        <p>When combined with 5-FU, the recommendation is&#x000a0;for providers to monitor complete blood counts (with differential), liver function tests, and electrolytes.&#x000a0;Patients who develop diarrhea should be monitored closely until resolution. Renal function requires monitoring in&#x000a0;older patients or those with known kidney disease/renal impairment.<xref ref-type="bibr" rid="article-21866.r24">[24]</xref></p>
      </sec>
      <sec id="article-21866.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Therapeutic dosing of folinic acid varies by indication, and there is no internationally accepted single gold-standard regimen.[3] Overdose is rare, and limited data is available about its&#x000a0;effects. As mentioned above, folinic acid is commonly used with other chemotherapy agents, and it is challenging to discern causal relationships. Overdose effects generally appear as extensions of the previously mentioned adverse effects.</p>
        <p>The toxic dose of folinic acid is unknown, and there is no reported antidote. However, there are reports that excessive folinic acid can nullify the therapeutic effects of specific chemotherapy agents.<xref ref-type="bibr" rid="article-21866.r25">[25]</xref> Therapeutic doses vary depending on the indication, and because multiple folinic acid-containing regimens can exist for a single indication, clinicians should seek and closely follow appropriate literature for individual cases.<xref ref-type="bibr" rid="article-21866.r6">[6]</xref></p>
      </sec>
      <sec id="article-21866.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing drug overdose and toxicities relative to chemotherapy regimens requires an interprofessional team of healthcare professionals, including physicians and specialists, advanced practice practitioners, nurses, laboratory technologists, and pharmacists. Without proper management, the morbidity and mortality from these regimens (ie, methotrexate, 5-FU) could significantly increase. Careful monitoring of gastrointestinal complications and abnormal lab values by clinicians should prompt a coordinated care effort that includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ordering hematologic studies (CBC with differential) and parameters indicating renal function (BUN, creatinine).</p>
          </list-item>
          <list-item>
            <p>Monitor the patient for signs and symptoms of neurological decline, gastrointestinal complications such as diarrhea or stomatitis, and anemia.</p>
          </list-item>
          <list-item>
            <p>Consult with the pharmacist about using chemotherapeutic agents with a precise record of timing and dosage.</p>
          </list-item>
          <list-item>
            <p>Consult the intensivist about ICU care and monitor if the patient becomes hemodynamically unstable.</p>
          </list-item>
        </list>
        <p>Managing malignancies and immunologic disorders is not a process that stops with the oncologist. Careful monitoring from the primary care team and nursing is imperative. A thorough drug administration record is crucial to identify and manage cases of overdose or toxic effects quickly. Nursing staff will often be on the front line to observe harmful effects and promptly report these to the rest of the clinical team. In addition to dosing and administration, the pharmacists must conduct thorough medication reconciliation and report any concerns to the healthcare team. Only by working as an interprofessional team can these outcomes be avoided. Several studies over 20 years have outlined the importance of folinic acid in chemotherapy. With many more ongoing studies, maintaining an up-to-date approach to patient care is necessary. Folinic acid therapy requires stringent dosing and administration timing to be effective.&#x000a0;</p>
      </sec>
      <sec id="article-21866.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21866&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21866">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21866/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21866">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21866.s11">
        <title>References</title>
        <ref id="article-21866.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scaglione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panzavolta</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Folate, folic acid and 5-methyltetrahydrofolate are not the same thing.</article-title>
            <source>Xenobiotica</source>
            <year>2014</year>
            <month>May</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>480</fpage>
            <page-range>480-8</page-range>
            <pub-id pub-id-type="pmid">24494987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Priest</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bunni</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>1991</year>
            <month>Dec</month>
            <day>18</day>
            <volume>83</volume>
            <issue>24</issue>
            <fpage>1806</fpage>
            <page-range>1806-12</page-range>
            <pub-id pub-id-type="pmid">1744924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Gramont</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Figer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Homerin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hmissi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cassidy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cortes-Funes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papamichael</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Bail</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Louvet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hendler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Braud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morvan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonetti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>16</issue>
            <fpage>2938</fpage>
            <page-range>2938-47</page-range>
            <pub-id pub-id-type="pmid">10944126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gustavsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Machover</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petrelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmoll</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Tveit</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A review of the evolution of systemic chemotherapy in the management of colorectal cancer.</article-title>
            <source>Clin Colorectal Cancer</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">25579803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaniboni</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>2432</fpage>
            <page-range>2432-41</page-range>
            <pub-id pub-id-type="pmid">9196159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Buddington</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Preventing and Managing Toxicities of High-Dose Methotrexate.</article-title>
            <source>Oncologist</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>12</issue>
            <fpage>1471</fpage>
            <page-range>1471-1482</page-range>
            <pub-id pub-id-type="pmid">27496039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiroky</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Neville</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Esdaile</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Choquette</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zummer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hazeltine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bykerk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kanji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St-Pierre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robidoux</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>795</fpage>
            <page-range>795-803</page-range>
            <pub-id pub-id-type="pmid">8507221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambie</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Drugs and folate metabolism.</article-title>
            <source>Drugs</source>
            <year>1985</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-55</page-range>
            <pub-id pub-id-type="pmid">3896745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanz-Altamira</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Ferrante</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Huberman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.</article-title>
            <source>Cancer</source>
            <year>1998</year>
            <month>Jun</month>
            <day>15</day>
            <volume>82</volume>
            <issue>12</issue>
            <fpage>2321</fpage>
            <page-range>2321-5</page-range>
            <pub-id pub-id-type="pmid">9635523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition.</article-title>
            <source>Oncology</source>
            <year>1997</year>
            <season>Jul-Aug</season>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>275</fpage>
            <page-range>275-80</page-range>
            <pub-id pub-id-type="pmid">9216850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vokes</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Schilsky</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Weichselbaum</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kozloff</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Panje</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.</article-title>
            <source>J Clin Oncol</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>241</fpage>
            <page-range>241-7</page-range>
            <pub-id pub-id-type="pmid">1688926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Neoptolemos</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stocken</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Almond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bassi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pederzoli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dervenis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fernandez-Cruz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lacaine</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pap</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spooner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kerr</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Friess</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>B&#x000fc;chler</surname>
                <given-names>MW</given-names>
              </name>
              <collab>European Study Group for Pancreatic Cancer</collab>
            </person-group>
            <article-title>Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Nov</month>
            <day>10</day>
            <volume>358</volume>
            <issue>9293</issue>
            <fpage>1576</fpage>
            <page-range>1576-85</page-range>
            <pub-id pub-id-type="pmid">11716884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klimo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.</article-title>
            <source>Ann Intern Med</source>
            <year>1985</year>
            <month>May</month>
            <volume>102</volume>
            <issue>5</issue>
            <fpage>596</fpage>
            <page-range>596-602</page-range>
            <pub-id pub-id-type="pmid">2580468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomblyn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiller</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Einsele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sepkowitz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Storek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wingard</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Boeckh</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>Center for International Blood and Marrow Research</collab>
              <collab>National Marrow Donor program</collab>
              <collab>European Blood and MarrowTransplant Group</collab>
              <collab>American Society of Blood and Marrow Transplantation</collab>
              <collab>Canadian Blood and Marrow Transplant Group</collab>
              <collab>Infectious Diseases Society of America</collab>
              <collab>Society for Healthcare Epidemiology of America</collab>
              <collab>Association of Medical Microbiology and Infectious Disease Canada</collab>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.</article-title>
            <source>Biol Blood Marrow Transplant</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1143</fpage>
            <page-range>1143-238</page-range>
            <pub-id pub-id-type="pmid">19747629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <collab>National Institutes of Health</collab>
              <collab>Centers for Disease Control and Prevention</collab>
              <collab>HIV Medicine Association of the Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>May</month>
            <volume>58</volume>
            <issue>9</issue>
            <fpage>1308</fpage>
            <page-range>1308-11</page-range>
            <pub-id pub-id-type="pmid">24585567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Touam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zingraff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jungers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chadefaux-Vekemans</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dr&#x000fc;eke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Massy</surname>
                <given-names>ZA</given-names>
              </name>
            </person-group>
            <article-title>Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy.</article-title>
            <source>Kidney Int</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>2292</fpage>
            <page-range>2292-6</page-range>
            <pub-id pub-id-type="pmid">10594808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amos</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Amess</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nancekievill</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Prevention of nitrous oxide-induced megaloblastic changes in bone marrow using folinic acid.</article-title>
            <source>Br J Anaesth</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-7</page-range>
            <pub-id pub-id-type="pmid">6607062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Apr</month>
            <day>06</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>682</fpage>
            <pub-id pub-id-type="pmid">28386133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greiner</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Zittoun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cheron</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1989</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-95</page-range>
            <pub-id pub-id-type="pmid">2789922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jardine</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Bleyer</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Intrathecal leucovorin after intrathecal methotrexate overdose.</article-title>
            <source>J Pediatr Hematol Oncol</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>302</fpage>
            <page-range>302-4</page-range>
            <pub-id pub-id-type="pmid">8689347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damaske</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Leucovorin-induced hypersensitivity reaction.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>136</fpage>
            <page-range>136-9</page-range>
            <pub-id pub-id-type="pmid">21248170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benchalal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yahchouchy-Chouillard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fouere</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fingerhut</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic shock secondary to intravenous administration of folinic acid: a first report.</article-title>
            <source>Ann Oncol</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>480</fpage>
            <page-range>480-1</page-range>
            <pub-id pub-id-type="pmid">11996482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kido</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tomikawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugimachi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas.</article-title>
            <source>Cancer</source>
            <year>1996</year>
            <month>Oct</month>
            <day>15</day>
            <volume>78</volume>
            <issue>8</issue>
            <fpage>1794</fpage>
            <page-range>1794-7</page-range>
            <pub-id pub-id-type="pmid">8859194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsalic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bar-Sela</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Beny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Visel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haim</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-6</page-range>
            <pub-id pub-id-type="pmid">12576935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21866.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machover</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chollet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zittoun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vandenbulcke</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Misset</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Schwarzenberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fourtillan</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.</article-title>
            <source>J Clin Oncol</source>
            <year>1986</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>685</fpage>
            <page-range>685-96</page-range>
            <pub-id pub-id-type="pmid">3517242</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
